Advertisement

Clinical Rheumatology

, Volume 34, Issue 12, pp 2097–2103 | Cite as

The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review

  • Yongpeng Ge
  • Hang Zhou
  • Jingli Shi
  • Bin Ye
  • Qinglin Peng
  • Xin Lu
  • Guochun WangEmail author
Original Article

Abstract

The purpose of this study is to examine the efficacy and safety of tacrolimus (FK506) in the management of polymyositis (PM)/dermatomyositis (DM). The Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, and China National Knowledge Infrastructure (CNKI) were searched to find articles published between May 1980 and April 2015 concerning tacrolimus therapy in PM/DM. The initial search yielded 107 articles. In the end, eight studies met our inclusion criteria and involved a total of 134 patients who received tacrolimus therapy for DM/PM. All studies were non-randomized. Oral tacrolimus of 0.075 mg/kg/day or 1.0–3.5 mg/d was administered twice daily or once daily together with glucocorticoids (GCs). According to comprehensive analysis of the studies, 93.3 % (42/45) and 64.7 % (11/17) of patients showed improvement in muscle strength and physical function status. The creatine kinase (CK) levels of 100 % (68/68) of patients decreased. The average dosage of GCs was reduced from 33.8 to 11.5 mg/day in PM/DM patients after the addition of tacrolimus. In the subject population, 65 patients had interstitial lung disease (ILD). After treatment, the forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) improved or stabilized in 89.3 % (25/28) and 81.3 % (13/16) of patients, respectively. The commonly adverse events were nephrotoxicity, hypomagnesemia, tremors, and hypertension, but they were slight among these patients. Current evidence appears to support the use of tacrolimus in refractory PM/DM and PM/DM-ILD patients. Tacrolimus seems to be a safe drug that improves both muscle strength and lung function, and it is well tolerated by patients. However, this conclusion should be confirmed by large-sample, randomized controlled studies.

Keywords

Idiopathic inflammatory myopathy Interstitial lung disease Tacrolimus 

Notes

Acknowledgments

This work was supported by the Science and Technology Commission Foundation of Beijing (No: Z121107001012005).

Disclosures

None.

References

  1. 1.
    Wallemacq PE, Verbeeck RK (2001) Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacol kinet 40:283–295CrossRefGoogle Scholar
  2. 2.
    Shimojima Y, Gono T, Yamamoto K et al (2004) Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis. Clin Rheumatol 23:262–265CrossRefPubMedGoogle Scholar
  3. 3.
    Hassan J, van der Net JJ, van Royen-Kerkhof A (2008) Treatment of refractory juvenile dermatomyositis with tacrolimus. Clin Rheumatol 27:1469–1471CrossRefPubMedGoogle Scholar
  4. 4.
    Ando M, Miyazaki E, Yamasue M et al (2010) Successful treatment with tacrolimus of progressive interstitial pneumonia associated with amyopathic dermatomyositis refractory to cyclosporine. Clin Rheumatol 29:443–445CrossRefPubMedGoogle Scholar
  5. 5.
    Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292:403–407CrossRefPubMedGoogle Scholar
  6. 6.
    American Thoracic Society, European Respiratory Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161:646–664CrossRefGoogle Scholar
  7. 7.
    Kurita T, Yasuda S, Oba K et al (2015) The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford) 54:39–44CrossRefGoogle Scholar
  8. 8.
    Yokoyama Y, Furuta S, Ikeda K et al (2015) Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis. Mod Rheumatol 16:1–22Google Scholar
  9. 9.
    Oddis CV, Sciurba FC, Elmagd KA et al (1999) Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 353:1762–1763PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Wilkes MR, Sereika SM, Fertig N et al (2005) Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 52:2439–2446CrossRefPubMedGoogle Scholar
  11. 11.
    Mitsui T, Kuroda Y, Ueno S et al (2011) The effects of FK506 on refractory inflammatory myopathies. Acta Neurol Belg 111:188–194PubMedGoogle Scholar
  12. 12.
    Shimojima Y, Ishii W, Matsuda M et al (2012) Coadministration of tacrolimus with corticosteroid accelerates recovery in refractory patients with polymyositis/dermatomyositis: a retrospective study. BMC Musculoskelet Disord 13:228–233PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Matsubara S, Kondo K, Sugaya K et al (2012) Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature. Clin Rheumatol 31:1493–1498CrossRefPubMedGoogle Scholar
  14. 14.
    Labirua-Iturburu A, Selva-O'Callaghan A, Martínez-Gómez X et al (2013) Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol 31:436–439PubMedGoogle Scholar
  15. 15.
    Ingegnoli F, Lubatti C, Ingegnoli A et al (2012) Interstitial lung disease outcomes by high-resolution computed tomography (HRCT) in Anti-Jo1 antibody-positive polymyositis patients: a single centre study and review of the literature. Autoimmun Rev 11:335–340CrossRefPubMedGoogle Scholar
  16. 16.
    Ge Y, Peng Q, Zhang S et al (2015) Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review. Clin Rheumatol 34:99–105CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2015

Authors and Affiliations

  • Yongpeng Ge
    • 1
  • Hang Zhou
    • 1
  • Jingli Shi
    • 1
  • Bin Ye
    • 1
  • Qinglin Peng
    • 1
  • Xin Lu
    • 1
  • Guochun Wang
    • 1
    Email author
  1. 1.Department of RheumatologyChina-Japan Friendship HospitalChaoyang DistrictChina

Personalised recommendations